PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity

Mirko Völkers, Shirin Doroudgar, Nathalie Nguyen, Mathias H. Konstandin, Pearl Quijada, Shabana Din, Luis Ornelas, Donna J. Thuerauf, Natalie Gude, Kilian Friedrich, Stephan Herzig, Christopher C. Glembotski, Mark A. Sussman

Research output: Contribution to journalArticlepeer-review

58 Scopus citations

Abstract

Diabetes is a multi-organ disease and diabetic cardiomyopathy can result in heart failure, which is a leading cause of morbidity and mortality in diabetic patients. In the liver, insulin resistance contributes to hyperglycaemia and hyperlipidaemia, which further worsens the metabolic profile. Defects in mTOR signalling are believed to contribute to metabolic dysfunctions in diabetic liver and hearts, but evidence is missing that mTOR activation is causal to the development of diabetic cardiomyopathy. This study shows that specific mTORC1 inhibition by PRAS40 prevents the development of diabetic cardiomyopathy. This phenotype was associated with improved metabolic function, blunted hypertrophic growth and preserved cardiac function. In addition PRAS40 treatment improves hepatic insulin sensitivity and reduces systemic hyperglycaemia in obese mice. Thus, unlike rapamycin, mTORC1 inhibition with PRAS40 improves metabolic profile in diabetic mice. These findings may open novel avenues for therapeutic strategies using PRAS40 directed against diabetic-related diseases.

Original languageEnglish (US)
Pages (from-to)57-65
Number of pages9
JournalEMBO Molecular Medicine
Volume6
Issue number1
DOIs
StatePublished - Jan 2014
Externally publishedYes

Keywords

  • Diabetes
  • MTOR
  • PRAS40

ASJC Scopus subject areas

  • Molecular Medicine

Fingerprint

Dive into the research topics of 'PRAS40 prevents development of diabetic cardiomyopathy and improves hepatic insulin sensitivity in obesity'. Together they form a unique fingerprint.

Cite this